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Introduction
When primary therapy of ovarian carcinoma fails, a cure is
generally impossible or extremely unlikely. Depending on the
time of recurrence, however, successful palliative treatment is
quite possible which, in addition to prolongation of life or the
disease-free interval, usually chiefly produces an improvement
in quality of life. With reference to the last point in particular,
treatments are necessary that are still effective after platinum
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pretreatment and which also have the lowest possible toxicity.
Up to now, it has generally been the rule to define two recur-
rence groups with different prognoses depending on the re-
sponse to their primary platinum-containing chemotherapy.
Patients who experience progression on chemotherapy with a
platinum agent or who have a recurrence within 6 months of
completing primary therapy are defined to have platinum-
refractory ovarian carcinoma. Patients with ‘platinum-sensitive’
ovarian carcinoma are those in whom a treatment-free interval
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Summary
Second-line and recurrence therapy in advanced ovarian carci-
noma is at present based more on clinical empiricism than on
data from prospective comparative studies. The resulting
uncertainty with respect to optimum treatment can only be
removed by consistent and systematic clinical research. For
this reason, the Ovarian Carcinoma Study Group in the
‘Arbeitsgemeinschaft Onkologie’ (AGO) has decided to offer
various studies not only for primary therapy but also for
second- and third-line situations where differentiation is made
in patients after paclitaxel/platinum pretreatment between
women with platinum-refractory carcinomas and recurrence
up to 6 months after completion of primary therapy, on the one
hand, and patients with platinum-sensitive carcinomas with
recurrence later than 12 months after completing primary
therapy, on the other hand. In addition, a newly defined group
with intermediate prognosis in whom the recurrence occurs
between 6 and 12 months after completion of primary therapy
has been included. A prospective randomized study is offered
for each of these patient groups in which patients with plati-
num/paclitaxel pretreatment can be enrolled. Only the co-
herent evaluation of various treatment modalities can lead to
an improvement in the quality of therapy in second- and third-
line situations.
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Zusammenfassung
Die Second-line- und Rezidivtherapie beim fortgeschrittenen
Ovarialkarzinom basiert zur Zeit mehr auf klinischer Empirie
als auf Daten prospektiver Vergleichsstudien. Die daraus fol-
gende Unsicherheit bezüglich einer optimalen Therapie kann
nur durch konsequente und systematische klinische Forschung
behoben werden. Deshalb hat sich die Studiengruppe Ovarial-
karzinom innerhalb der Arbeitsgemeinschaft Onkologie (AGO)
entschlossen, nicht nur für die Primärtherapie, sondern auch
für die Second- und Third-line-Situation verschiedene Studien
anzubieten. Bei Patientinnen nach Paclitaxel/Platin-Vorbe-
handlung wird hier unterschieden zwischen Frauen mit platin-
refraktärem Karzinom und Rezidiv bis 6 Monate nach Ab-
schluß der Primärtherapie einerseits und Patientinnen mit
platinsensiblem Karzinom mit Auftreten eines Rezidivs später
als 12 Monate nach Abschluß der Primärtherapie andererseits.
Zusätzlich neu definiert wurde die sogenannte prognostisch
intermediäre Gruppe, bei der das Rezidiv zwischen 6 und 
12 Monate nach Abschluß der Primärtherapie auftritt. Für
jede dieser Patientengruppen wird eine prospektiv randomi-
sierte Studie angeboten, in die Patientinnen mit Platin/Pacli-
taxel-Vorbehandlung eingebracht werden können. Nur durch
die konsequente Evaluierung der verschiedenen Therapiemo-
dalitäten kann es zu einer Verbesserung der Therapiequalität
in der Second- und Third-line-Therapie kommen.
of at least 6 months can be achieved after response to primary
therapy.
By including paclitaxel in the primary therapy, it has been pos-
sible to significantly prolong both progression-free and overall
survival rates in patients with residual tumors in comparison to
patients who previously had received standard therapy con-
sisting of platinum analogs and cyclophosphamide. The im-
provements are, however, bought at the cost of higher toxicity
rates, which are more or less pronounced depending on
whether cisplatin or carboplatin was used as the combination
partner. Thus, a not insubstantial percentage of patients who
received primary therapy with platinum and paclitaxel exhi-
bited considerable neurotoxicity which was still objectively
demonstrable even several months after completing primary
therapy. These patients are usually not willing to undergo
renewed platinum/paclitaxel therapy in the case of recurrence
within 12 months after completion of primary therapy. There-
fore it is usefull to re-evaluate or redefine the original classifi-
cation into only two different prognostic groups at risk of re-
currence. In addition to the platinum-resistant and platinum-
sensitive ovarian carcinomas, it would be reasonable to define
an intermediate prognostic group of patients who relapse 
within a period of 6 and 12 months after completion of primary
chemotherapy with platinum/paclitaxel.
The response rates to treatment in platinum-refractory ovarian
carcinomas are generally poor and remission rates of more
than 20% are rare. Therefore, especially in this situation, it is
important to use agents with an optimal side-effect profile and
low toxicity. To what extent one resorts to long-known drugs
such as treosulfan, etoposide, hexamethylmelamine, epirubi-
cin, cyclophosphamide or one uses newer substances such as
topotecan, gemcitabine, vinorelbine or liposomal doxorubicin
must generally be decided individually according to the cur-
rent evidence in the literature. The survival data are poor,
even in studies yielding better results, and generally predict
less than 1 year. These overall poor results show that the assess-
ment of the response rate in such patients is not necessarily
equivalent to the efficacy of the treatment. As there is only a
very slight survival advantage, even in situations with an ini-
tially high response rate, aspects such as quality of life during
treatment or the spectrum of side effects gain increasing im-
portance. As the assessment of all these aspects can only be
reliably carried out in comparative prospective randomized
studies, various treatment concepts for second- and third-line
therapy of ovarian carcinoma have been developed for the
Ovarian Carcinoma Study Group within the Arbeitsgemein-
schaft Gynäkologische Onkologie (AGO). All of these studies
are characterized by effective monitoring and obligatory docu-
mentation of quality of life.
Platinum-Refractory Carcinoma
In platinum-refractory ovarian carcinoma with recurrence
during primary therapy or within 6 months of its completion,
the overall unsatisfactory results merit consideration of other
alternative treatments. One possibility in this situation are
endocrine forms of treatment, such as GnRH analogs, tamo-
xifen or gestagens.
Study of Treosulfan versus Leuprorelin Acetate
The study of treosulfan 7 g/m2, day 1, versus leuprorelin ace-
tate 3.75 mg, day 1, every 4 weeks was initiated by the Ovarian
Carcinoma Study Group for this group of patients. Here the
question of prime interest was whether the probably low-side-
effect endocrine therapy is equivalent to chemotherapy with
treosulfan, also considered to be mild. Leuprorelin acetate was
selected because previous studies had demonstrated at least a
certain degree of response. In principle, tamoxifen showed
approximately equivalent response rates with an equally low
side-effect rate, but leuprorelin was given preference in the
end. While gestagens show an excellent roborant effect, this
group of drugs was not considered as the reference substance
because of their considerably lower response rate of 3%.
Ovarian Carcinoma with Intermediate Prognosis
For these patients who relapse within 6 to 12 months after
completion of primary therapy, re-induction with platinum
analogs can be considered. As already mentioned above, how-
ever, many patients reject restarting treatment with the
primarily used agents because of the persistent toxicity.
Study of Topotecan versus Treosulfan
There are only few studies available on second-line therapy
after platinum/paclitaxel pretreatment. In view of the current
data situation it therefore seems reasonable to compare agents
with low side effects on the one hand and new substances 
on the other. To this aim, the Ovarian Carcinoma Study 
group within the AGO has initiated a study comparing treo-
sulfan 7 g/m2, day 1, and topotecan 1.5 mg/m2, days 1–5, with
respect to survival, toxicity and, especially, quality of life.
Secondary criteria are progression-free survival and the remis-
sion rate. Inclusion criteria for this study are initial proof of an
epithelial ovarian tumor, platinum/paclitaxel pretreatment,
and recurrence within 6 to 12 months after completion of pri-
mary chemotherapy. Exclusion criteria are – as commonly
defined – secondary malignancies, pretreatment with more than
one chemotherapy regimen in a second-line situation, and
serious medical diseases. If hematological side effects occur,
the dose should be reduced initially. The addition of G-CSF is
not envisaged for the primary study. Indications for dose re-
duction are febrile neutropenia or grade IV thrombocyto-
penia. A reduction of the neutrophils to less than 500 for more
than 5 days or less than 100 for more than 3 days are reasons
for dose reduction, which is carried out from an initial level of
1.5 mg/m2 topotecan in increments of 0.25 mg each to 1 mg/m2.
Treosulfan is reduced from an initial dose of 7 g/m2 to 5 or
4 g/m2. If the treatment cannot be adequately administered in
spite of corresponding reductions, the study must be termin-
ated. Further criteria for dropout were defined as the patient’s
wishes first of all, then intolerable side effects and disease
progression during therapy.
This study is also available for patients in a third-line situation,
i.e., those in whom platinum re-induction has already been
carried out for late recurrence after primary therapy with
platinum or paclitaxel. Here the starting doses, however, are
1.25 mg/m2 of topotecan and 5 g/m2 of treosulfan. When marked
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hematological side-effects occur, the dose is reduced once ini-
tially followed by discontinuation of the study if the therapy
cannot be adequately carried out.
In principle, these two patient populations, i.e. with recurren-
ce 6 to 12 months after completion of therapy or progression
after re-induction of platinum for late recurrence, involve the
same basic situation. The prognosis for both the patients who
develop a recurrence 6 to 12 months after primary therapy
and those who have shown renewed progression after pla-
tinum re-induction for late recurrences can be regarded as
being approximately the same. With respect to the side-effect
rate and therapeutic response, however, this study will be
stratified into second- and third-line. The essential difference
is marked in the initial dosage, as more hematological side
effects are to be expected in the third-line situation. Recruit-
ment is planned to include a total of 120 patients over 2 years;
45 patients have already been enrolled in the study within the
first 6 months.
Late Recurrence
Patients who develop a ‘late recurrence’ after platinum/pacli-
taxel pretreatment can be successfully treated with platinum
once more. The study of carboplatin vs. carboplatin/paclitaxel
originally planned by the AGO Ovarian Carcinoma Group
could not be continued because of lack of acceptance by the
patients (see above). Instead, a new study has been initiated
comparing carboplatin as single-agent therapy with a combi-
nation of carboplatin and gemcitabine. However, the study is
in the initial phase so that at the moment not even preliminary
results can be presented.
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